These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 10417749

  • 1. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS, Robson MC, Smiell JM, Perry BH.
    Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH.
    Wound Repair Regen; 1999 May; 7(5):335-46. PubMed ID: 10564562
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ.
    Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [Abstract] [Full Text] [Related]

  • 5. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.
    Wound Repair Regen; 2000 Aug; 8(3):162-8. PubMed ID: 10886806
    [Abstract] [Full Text] [Related]

  • 6. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
    Smiell JM.
    Am J Surg; 1998 Aug; 176(2A Suppl):68S-73S. PubMed ID: 9777975
    [Abstract] [Full Text] [Related]

  • 7. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.
    Mustoe TA, Cutler NR, Allman RM, Goode PS, Deuel TF, Prause JA, Bear M, Serdar CM, Pierce GF.
    Arch Surg; 1994 Feb; 129(2):213-9. PubMed ID: 8304833
    [Abstract] [Full Text] [Related]

  • 8. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers.
    Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF.
    Lancet; 1992 Jan 04; 339(8784):23-5. PubMed ID: 1345953
    [Abstract] [Full Text] [Related]

  • 9. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
    Guzman-Gardearzabal E, Leyva-Bohorquez G, Salas-Colín S, Paz-Janeiro JL, Alvarado-Ruiz R, García-Salazar R.
    Adv Ther; 2000 Jan 04; 17(4):184-9. PubMed ID: 11185057
    [Abstract] [Full Text] [Related]

  • 10. [Becaplermin gel (Regranex gel)].
    Senet P.
    Ann Dermatol Venereol; 2004 Apr 04; 131(4):351-8. PubMed ID: 15258509
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
    Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP.
    Adv Skin Wound Care; 2005 Jun 04; 18(5 Pt 1):258-66. PubMed ID: 15942317
    [Abstract] [Full Text] [Related]

  • 14. Becaplermin.
    Balfour JA, Noble S.
    BioDrugs; 1999 May 04; 11(5):359-64. PubMed ID: 18031145
    [Abstract] [Full Text] [Related]

  • 15. Original articles: ease of wound closure as an endpoint of treatment efficacy.
    Robson MC, Maggi SP, Smith PD, Wassermann RJ, Mosiello GC, Hill DP, Cooper DM.
    Wound Repair Regen; 1999 May 04; 7(2):90-6. PubMed ID: 10231510
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000 May 04; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 18. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
    Castronuovo JJ, Ghobrial I, Giusti AM, Rudolph S, Smiell JM.
    Am J Surg; 1998 Aug 04; 176(2A Suppl):61S-67S. PubMed ID: 9777974
    [Abstract] [Full Text] [Related]

  • 19. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
    Steed DL.
    Plast Reconstr Surg; 2006 Jun 04; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
    [Abstract] [Full Text] [Related]

  • 20. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB.
    Pierce GF, Tarpley JE, Allman RM, Goode PS, Serdar CM, Morris B, Mustoe TA, Vande Berg J.
    Am J Pathol; 1994 Dec 04; 145(6):1399-410. PubMed ID: 7992843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.